netFormulary NHS
Bedfordshire and Luton Joint Formulary
Bedford Hospital NHS Trust
Bedfordshire CCG
Luton & Dunstable University Hospital NHS Foundation Trust
Luton CCG
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing

 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Abemaciclib (Verzenios®)
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the NICE TA below.

 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
Atezolizumab 1200mg (Tecentriq®)
(Intravenous infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Funding approval required.

Approved, in accordance with the Cancer Drugs Fund, for the first line treatment of locally advanced or metastatic urothelial cancer in patients who are ineligible for cisplatin-based chemotherapy. NICE TA492.

Funding approval required for use in line with the other NICE TA's below.

 

 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA584 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
   
Avelumab 20mg/mL (Bavencio®)
(Concentrate for infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Cancer Drug Funded in accordance with criteria in NICE TA517.

 
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
   
Cytotoxic Drug Axicabtagene ciloleucel  (Yescarta®)
(Infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Cancer Drug Funded in accordance with criteria in NICE TA559.

 
Link  NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
   
Axitinib (Inlyta®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted to prescribing in accordance with NICE TA333. 
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Binimetinib 15mg (Mektovi®)
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use with encorafenib in accordance with the NICE TA below.

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Bosutinib (Bosulif®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Restricted - prescribing by Oncologists according to NICE TA401.  
Link  NICE TA401: Bosutinib for previously treated CML.
   
Cytotoxic Drug Brentuxumab (Adcetris®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Restricted - prescribing by Oncologists according to NICE TA524.

 
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
   
Brigatinib (Alunbrig®)
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with the NICE TA below.

 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
   
Carfilzomib 10mg. 30mg, 60mg (Kyprolis®)
(Intravenous infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in line with NICE TA457 for previously treated multiple myeloma. 
Link  NICE TA457:Carfilzomib for previously treated multiple myeloma
   
Cemiplimab  (Libtayo®)
(350 mg concentrate for solution for infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary homepage.

Restricted to prescribing in accordance with the following NICE TA (funded by the Cancer Drugs Fund):-

 

 
Link  NICE TA 592 Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
   
Cytotoxic Drug Ceritinib (Zykadia)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Restricted - for use by Oncologists in line with NICE TA395 and TA500.

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Crizotinib (Xalkori®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

Commissioned by Not NHSNHS England.
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be prescribed by specialists in line with NICE TA422 and TA529.

 
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase- positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Dabrafenib (Tafinlar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted to prescribing in accordance with NICE TA's below.

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Link  NICETA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
   
Dacomitinib (Vizimpro®)
(15mg, 30mg and 45mg film-coated tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
NHS England
BlueTeq

FOR ALL PRESCRIBING - Blueteq or high cost drug form required - see link from formulary homepage.

To be prescribed by specialists in line with the following NICE TA(s):-

 
Link  TA595 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Cytotoxic Drug Daratumumab 20mg/mL (Darzalex®)
(Concentrate for infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Funded by Cancer Drugs Fund if criteria fulfilled in the NICE TAs below.

 
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
Cytotoxic Drug Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
To be prescribed by specialists in line with NICE TA425 and TA426. 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Durvalumab (50 mg/ml concentrate solution for infusion Imfinzi®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Home Page.

Funded by the Cancer Drugs Fund if criteria fulfilled as per the following NICE TA (s)

 
Link  NICE TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
   
Encorafenib 50mg, 75mg (Braftovi ®)
(Capsules)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use with binimetinib in accordance with the NICE TA below.

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Commissioned by Not NHSNHS England.

To be prescribed by specialists in line with NICE TA423 & TA515.

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer
Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
   
Ibrutinib 140mg (Imbruvica®)
(Capsules)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Blueteq or High cost drug form required – see link from Formulary homepage.

To be prescribed by Haematologists in line with NICE TA's below.

 
Link  MHRA DSU Aug 17: Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
Link  NICE TA429: Ibrutinib for previously treated CLL
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Idelalisib (Zydelig®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
100mg Tablets

Approved in accordance with NICE TA359 for the treatment of chronic lymphocytic leukaemia

Restricted - must only be prescribed by staff with specialist training in Oncology or Haematology  
Link  MHRA Drug Safety Update (May 2016) - Idelalisib (Zydelig▼): interim measures following signal of serious infection and deaths related to infection found in clinical trials
Link  NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
   
Ixazomib (Ninlaro®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Funding approval required.

Funded by Cancer Drug Fund when prescribed  with lenalidomide and dexamethasone for the treatment of multiple myeloma by Oncologist according to NICE TA505.

 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
   
Lenvatinib (Lenvima®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Prescribing by specialist in line with the NICE TA's below.

 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
   
Cytotoxic Drug Midostaurin 25mg (Rydapt®)
(Capsules)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Prescribing by specialist in line with NICE TA523.

 
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
   
Cytotoxic Drug Niraparib 100mg (Zejula®)
(Capsules)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Funded by Cancer Drug Fund. Prescribing by specialist in line with NICE TA528.

 
Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
   
Cytotoxic Drug Olaparib (Lynparza®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

50mg hard capsules

100mg and 150mg film-coated tablets

Approved in accordance with the following NICE TA(s). NB NICE TA 598 indications are funded via the Cancer Drugs Fund.

 

 
Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer
Link  TA598 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
   
Cytotoxic Drug Panitumumab (Vectibix®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

20 mg/mL concentrate for solution for infusion

Approved in accordance with NICE TA 439 

 

 
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
Cytotoxic Drug Panobinostat (Farydak®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
20mg Capsules

Approved in accordance with NICE TA380.


 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Pembrolizumab (Keytruda®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage. OR may be funded through the Cancer Drug Fund.
50mg Powder for concentrate for solution

Approved in accordance with the NICE TA's below.

 
Link  DSU June 2017: Nivolumab, pembrolizumab: reports of organ transplant rejection
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive NSC lung cancer
Link  NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522:Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Link  NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
   
Cytotoxic Drug Pertuzumab (Perjeta®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
To be prescribed by specialists in line with NICE TA's below or CDF advanced breast cancer criteria.

 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
   
Ponatinib 15mg, 30mg, 45mg (Iclusig®)
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
Approved in accordance with NICE TA451 for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. 
Link  MHRA DSU Oct 2018: Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Ruxolitinib (Jakavi®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
5mg, 10mg & 15mg Tablets

Approved in accordance with NICE TA386  
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Cytotoxic Drug Tisagenlecleucel (Kymriah®)
(Infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Cancer Drug Funded in accordance with criteria in NICE TA's below.

 

 
Link  NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Link  NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
   
Tivozanib 890mcg, 1340mcg (Fotivda®)
(Capsules)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

For specialist prescribing in line with NICE TA512.

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
Trametinib (Mekinist®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Restricted - for Oncologists in line with the NICE TA's below.

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
Venetoclax 10mg, 50mg, 100mg (Venclyxto®)
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Approved in accordance with NICE TA's below.

 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
   
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
Cytotoxic Drug Arsenic Trioxide (Trisenox®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Restricted - prescribing by Oncologists according to NICE TA526

 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
   
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib (Velcade®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
3.5mg Injection
unlicensedunlicensed 1.25mg/0.5mL, 1.5mg/0.6mL, 1.75mg/0.7mL, 1.8mg/0.72mL, 2mg/0.8mL, 2.2mg/0.88mL, 2.25mg/0.9mL & 2.5mg/1mL Subcutaneous Injection
unlicensedunlicensed 1.5mg - 2.7mg in 0.9% Sodium Chloride Injection

Approved in accordance with NICE TAs outlined below.

Restricted - must only be prescribed by staff with specialist training in Oncology or Haematology

 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Link  NICE TA299: Leukaemia (chronic myeloid) - bosutinib
Link  NICE TA311: Multiple myeloma - bortezomib (induction therapy
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Link  NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotin 50mg (Adcetris®)
(Intravenous infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with NICE TA446 & TA478. 
Link  NICE TA 577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA8524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
   
08.01.05  Expand sub section  Cetuximab
Cetuximab (Erbitux®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
100mg/20mL & 500mg/100mL Injection
450mg - 1050mg in 0.9% Sodium Chloride Infusion (250mL)

Approved in accordance with NICE TA242, TA118, TA439 & TA473.

 
Link  NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Link  NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
   
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
Cytotoxic Drug Temozolomide (Temodal®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with NICE TA23 & TA121 
Link  NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Link  NICE TA23: Brain cancer - temozolomide
   
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
100mg Film Coated Tablets
300mg & 500mg Capsules
500mg/5mL Liquid

 
   
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Ipilimumab (Yervoy®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted - prescribing by Consultant Oncologists in accordance with NICE TA268, NICE TA319 or NICE TA400. 
Link  NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
   
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin (Nipent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
10mg Injection
unlicensedunlicensed 8mg in 0.9% Sodium Chloride Infusion (50mL)

Restricted - must only be prescribed by staff with specialist training in Oncology or Haematology  
   
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
unlicensedunlicensed 75mg - 800mg in 5% Glucose Infusion (500mL)

Restricted - must only be prescribed by staff with specialist training in Oncology or Haematology  
   
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
unlicensedunlicensed 26mg - 160mg in 0.9% Sodium Chloride Infusion (1000mL)

Restricted - must only be prescribed by staff with specialist training in Oncology or Haematology  
   
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
unlicensedunlicensed 75mg - 260mg in 5% Glucose Infusion (250mL)
unlicensedunlicensed 150mg - 270mg in 5% Glucose Infusion (500mL)

Approved in accordance with NICE TA100

Restricted - must only be prescribed by staff with specialist training in Oncology or Haematology  
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
50mg Capsules

Restricted - must only be prescribed by staff with specialist training in Oncology or Haematology  
   
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib (Giotrif®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
20mg, 30mg, 40mg & 50mg Tablets

Approved in accordance with NICE TA310 for the treatment of metastatic non-small-cell lung cancer.

 
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
   
Cytotoxic Drug Alectinib 150mg (Alecsena®)
(Capsules)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Approved in accordance with NICE TA536.

 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
   
Cabozantinib (Cabometyx®)
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved according to NICE TA's below.

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Cytotoxic Drug Cabozantinib (Cometriq®)
(Capsules)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved according to NICE TA516.

 
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
   
Erlotinib (Tarceva®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
100mg & 150mg Tablets

Restricted to prescribing in line with NICE TA258 & TA374. 
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Commissioned by Not NHSNHSEngland for some indications.
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be prescribed by specialists in line with NICE TA421, TA432 & TA449. 
Link  NICE TA421: Everolimus with Exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
250mg Film Coated Tablets

Approved in accordance with NICE TA192 for the treatment of locally advanced or metastatic non-small-cell lung cancer.  
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
   
Cytotoxic Drug Imatinib (Gilvec®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
100mg & 400mg Tablets

Approved in accordance with the NICE TA's below.

Restricted - must only be prescribed by staff with specialist training in Oncology or Haematology  
Link  NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating resistant CML
Link  NICE TA426: Dasatinib, nilotinob and imatinib for untreated CML
Link  NICE TA70: Leukaemia (chronic myeloid) - imatinib
Link  NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
   
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
150mg & 200mg Capsules

Approved in accordance with NICE TA425 and 426 for untreated chronic myeloid leukaemia.

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating resistant CML
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated CML
   
Nintedanib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
100mg & 150mg Capsules

Approved in accordance with NICE TA347 for the treatment of metastatic non-small-cell lung cancer.  
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
   
Palbociclib 75mg, 100mg, 125mg (Ibrance®)
(Capsules)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage. 

Approved in accordance with NICE TA495.

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in line with NICE TA215. 
Link  NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
   
Regorafenib 40mg (Stivarga® )
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with the NICE TA's below.

 
Link  NICE TA488:Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
   
Ribociclib 200mg
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage. 

Approved in accordance with the following NICE TA(s):-

(NB For TA593, funding is via the Cancer Drugs Fund)

 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  TA593 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
   
Sorafenib 200mg (Nexavar®)
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

HIgh cost drug (Cancer Drug Fund).

Prescribing by specialists in line with NICE TA474 and TA535.

 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Sunitinib (Sutent®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in line with NICE TA's below.  
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA178: Renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Vemurafenib (Zelboraf®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in line with NICE TA176 & TA269.  
Link  MHRA Drug Safety Update (November 2015) - Vemurafenib (Zelboraf▼): risk of potentiation of radiation toxicity
Link  NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Link  NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING - a completed and approved HIGH COST DRUG compliance form, via BLUETEQ, is required.
Restricted - prescribing by Consultant Oncologists in line with NICE TA391
 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Docetaxel (Taxotere®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red

10mg/0.5mg & 20mg/1mL Injection
unlicensedunlicensed 60mg - 190mg in 0.9% Sodium Chloride Infusion (250mL)

Approved in accordance with NICE TA's below for the treatment of early node-positive breast cancer and hormone-refractory metastatic prostate cancer. For more information click the link below

 
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with NICE TA389 & TA108 for the treatment of node-positive breast cancer and recurrent ovarian cancer.

 
Link  NICE TA108: Breast cancer (early) - paclitaxel
Link  NICE TA55: Ovarian cancer - paclitaxel (review)
   
Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Abraxane®)
(Intravenous infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for the treatment of breast cancer in patients who have documented Taxane hypersensitivity, in accordance with routine NHSE commissioning.
Approved in accordance with TA476 for untreated metastatic pancreatic cancer. 
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
Restricted - must be prescribed only by staff with specialist training in Oncology in line with NICE guidelines.  
Link  NICE CG131: Colorectal cancer: diagnosis and management
   
Cytotoxic Drug Topotecan (Hycamtin®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
250microgram & 1mg Capsules

Approved in accordance with NICE TA389, TA184 & TA183. 
Link  NICE TA183: Cervical cancer (recurrent) - topotecan
Link  NICE TA184: Lung cancer (small-cell) - topotecan
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin (Yondelis®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

0.25mg and 1 mg powder for concentrate for solution for infusion.

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accrodance with NICE TA185 and TA389

 

 
Link  NICE TA185: Soft tissue sarcoma - trabectedin
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trastuzumab to top
Cytotoxic Drug Trastuzumab (Herceptin®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
150mg Injection
100mg & 160mg Injection for Infusion
147mg - 1200mg in 0.9% Sodium Chloride Infusion (250mL)

Approved in accordance with NICE TA's below.  
Link  NICE TA107: Breast cancer (early) - trastuzumab
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in line with NICE TA458 
Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
   
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
Cytotoxic Drug Vismodegib 150mg (Erivedge®)
(Capsules)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Only approved in accordance with the National Cancer Drugs Fund List for the treatment of locally advanced or metastatic Basal Cell Carcinoma. See NICE TA489.

Note: Patient, prescriber, and supplying pharmacy must comply with the manufacturer’s pregnancy prevention programme.  
Link  NICE TA489: Vismodegib for treating basal cell carcinoma
   
 ....
 Non Formulary Items
Cytotoxic Drug  Aflibercept  (Zaltrap®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Not recommended by NICE for malignant indications.

Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
 
Cytotoxic Drug  Amsacrine  (Amsidine®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Bevacizumab  (Avastin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
No malignant indications have been approved by NICE.

Link  MHRA Drug Safety Update (January 2011) - Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Link  NICE TA214: Breast Cancer with taxane
Link  NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Link  NICE TA263: Breast cancer with capecitabine
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
 
Bexarotene  (Targretin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Crisantaspase  (Erwinase®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Dacarbazine

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Erlotinib  (Tarceva® )

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Link  NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Link  NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
 
Hydroxycarbamide  (Hydrea®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Lapatinib  (Tyverb®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
 
Mitotane  (Lysodren®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Necitumumab

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
Olaratumab  (Lartruvo®)
(Intravenous infusion)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

Marketing authorisation and NICE TA465 withdrawn July 2019.

No new patients to be initiated and existing patients are no longer funded by NHS England.

Link  MHRA DSU June 2019: Lartruvo¥ (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy
Link  NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
 
Pablociclib  (Ibrance®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Porfimer Sodium  (Photofrin ®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ramucirumab  (Cyramza®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
 
Sonidegib  (Odomzo®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Talimogene laherparepvec  (Imlygic®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Temoporfin  (Foscan®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Temsirolimus  (Torisel®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
 
Tretinoin  (Vesanoid®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Vandetanib  (Caprelsa®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
 
Vosaroxin  (Qinprezo)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment  

Amber

Amber medicines are considered suitable for GP prescribing following specialist initiation.  

Green

These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations   

Amber SCG

Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.   

Black

A decision has been made by either or both the local or national NHS not to routinely commission this preparation for its licensed indications. Do not prescribe.   

netFormulary